We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

81 hedge funds and large institutions have $715M invested in Quince Therapeutics in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 4

320% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 10

37% more capital invested

Capital invested by funds: $523M → $715M (+$192M)

29% more funds holding

Funds holding: 63 → 81 (+18)

0.07% more ownership

Funds ownership: 0.19% → 0.26% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
81
Holders Change
+18
Holders Change %
+28.57%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
22
Increased
42
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$85.3M
2
Capital International Investors
Capital International Investors
California
+$36.5M
3
BlackRock
BlackRock
New York
+$11.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.9M
5
ECG
EPIQ Capital Group
California
+$6.8M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.14M
2
Invesco
Invesco
Georgia
-$659K
3
AA
ALPS Advisors
Colorado
-$394K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$284K
5
N
Natixis
France
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$1.3M +$687K +75 +114%
Renaissance Technologies
27
Renaissance Technologies
New York
$1.25M +$1.01M +110 +440%
Millennium Management
28
Millennium Management
New York
$1.17M -$18.3K -2 -2%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$1.1M +$284K +31 +35%
UBS Group
30
UBS Group
Switzerland
$1.06M -$137K -15 -12%
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$956K +$321K +35 +51%
AllianceBernstein
32
AllianceBernstein
Tennessee
$926K +$238K +26 +35%
Wells Fargo
33
Wells Fargo
California
$859K +$128K +14 +18%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$857K +$45.8K +5 +6%
Marshall Wace
35
Marshall Wace
United Kingdom
$735K +$577K +63 +394%
Victory Capital Management
36
Victory Capital Management
Texas
$727K +$577K +63 +394%
Squarepoint
37
Squarepoint
New York
$699K +$266K +29 +63%
Morgan Stanley
38
Morgan Stanley
New York
$668K +$183K +20 +38%
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$667K +$183K +20 +38%
Citigroup
40
Citigroup
New York
$654K +$495K +54 +318%
SSA
41
Schonfeld Strategic Advisors
New York
$631K +$623K +68 New
N
42
Natixis
France
$564K -$202K -22 -27%
Two Sigma Investments
43
Two Sigma Investments
New York
$501K +$495K +54 New
JP Morgan Chase
44
JP Morgan Chase
New York
$481K -$183K -20 -28%
Norges Bank
45
Norges Bank
Norway
$463K +$458K +50 New
UBS AM
46
UBS AM
Illinois
$447K +$440K +48 New
AIG
47
American International Group
New York
$445K +$128K +14 +41%
SFI
48
Susquehanna Fundamental Investments
Pennsylvania
$439K +$431K +47 New
CS
49
Credit Suisse
Switzerland
$435K +$431K +47 New
LBC
50
Lawrence B. Cohen
$417K – – –
1
2
3 4

QNCX Hedge Fund Activity: Q2 2020 in Review

81 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2020, worth a combined $715M — up 37% from $523M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new QNCX positions and 4 closed out — a net gain of 18 holders — while 42 added to existing stakes and 10 trimmed.

The largest buyer was Capital World Investors, adding an estimated $85.3M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.14M sold.

  • 81 institutional investors held Quince Therapeutics (QNCX) as of Q2 2020, up from 63 in Q1 2020.
  • Funds reported $715M of Quince Therapeutics stock for Q2 2020, up 37% quarter-over-quarter.
  • 22 funds opened new Quince Therapeutics positions in Q2 2020 and 4 closed out, a net change of +18 holders.
  • The largest Quince Therapeutics buyer in Q2 2020 was Capital World Investors, an estimated $85.3M added.
  • The largest Quince Therapeutics seller in Q2 2020 was Ikarian Capital, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2020.